JNJ-40411813

JNJ-40411813 is an experimental drug developed by Janssen Pharmaceutica, a division of Johnson & Johnson. It is a positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (α7 nAChR), which is believed to play a crucial role in cognitive function.

Mechanism of Action

JNJ-40411813 works by enhancing the activity of the α7 nAChR. This receptor is a type of ionotropic receptor that, when activated, allows the flow of ions across the cell membrane. The α7 nAChR is particularly important in the brain, where it is involved in a variety of cognitive processes.

Clinical Trials

JNJ-40411813 has undergone Phase II clinical trials for the treatment of schizophrenia and Alzheimer's disease. In these trials, the drug was found to improve cognitive function in patients with schizophrenia and to have a potential benefit in Alzheimer's disease.

Side Effects

As with any drug, JNJ-40411813 has potential side effects. These include nausea, vomiting, and headache. However, these side effects were generally mild and did not lead to discontinuation of the drug in the clinical trials.

Future Research

Further research is needed to fully understand the potential benefits and risks of JNJ-40411813. This includes additional clinical trials and studies to investigate the drug's mechanism of action.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian